Zachary Pinchover
Pulmonary Disease · Austin, TXNPI 1073040044
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,957 of the $2,206 with a category attached, or 88.7%. It is spread thinly across 19 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $973, 4.5 times the $216 reported in 2022. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 78 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$323
- GSK$311
- Astellas Pharma US Inc$306
- Regeneron Healthcare Solutions, Inc.$216
- United Therapeutics Corporation$192
- Actelion Pharmaceuticals US, Inc.$144
- plus $714 from 13 others
What the payments were for
- Food & beverage$1,95789%
- Education$24911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $323 |
| GSK | 13 | $311 |
| Astellas Pharma US Inc | 6 | $306 |
| Regeneron Healthcare Solutions, Inc. | 2 | $216 |
| United Therapeutics Corporation | 11 | $192 |
| Actelion Pharmaceuticals US, Inc. | 9 | $144 |
| Galvanize Therapeutics, Inc | 1 | $122 |
| Sanofi | 6 | $114 |
| Intuitive Surgical | 1 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Viatris Specialty LLC | 3 | $61 |
| Mylan Specialty L.p. | 3 | $55 |
| La Jolla Pharmaceutical Company | 3 | $55 |
| Bayer | 3 | $46 |
| Novo Nordisk | 2 | $33 |
| AbbVie | 1 | $19 |
| Pfizer | 1 | $17 |
| Insmed, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$125
- ALIYA SYSTEM$122
- AREXVY$111
- TEZSPIRE$109
How this compares
$2,206 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Austin
- John DallasAustin$81K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.